MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, LRMR had $69,553K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$69,553K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Stock-based compensation expense
-3,662
Net loss
--55,463
Prepaid expenses and other current assets
--4,818
Other assets
--35
Accrued expenses
-479
Accounts payable
-1,722
Depreciation expense
-175
Amortization of premium on marketable securities
--1,216
Lease expense
--133
Net cash used in operating activities
--45,921
Maturities of marketable securities
-113,500
Purchases of property and equipment
-68
Purchases of marketable securities
-80,142
Net cash provided by (used in) investing activities
-33,290
Net cash provided by financing activities
-0
Net increase in cash, cash equivalents and restricted cash
69,553 -12,631
Cash and cash equivalents at beginning of period
33,824 -
Cash and cash equivalents at end of period
90,746 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics, Inc. (LRMR)